IPO Details
| IPO Date | 24 to 27 Aug, 2026 |
| Listing Date | Tue, Sep 1, 2026 |
| Face Value | ₹ 2 per share |
| Price Band | ₹938 to ₹988 |
| Lot Size | 15 Shares |
| Sale Type | Fresh capital cum OFS |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE, NSE |
| Employee Discount | ₹ 90.00 |
| Total Issue Size | 1,77,86,442 shares (agg. up to ₹ 1,757 Cr) |
| Fresh Issue | 15,21,261 shares (agg. up to ₹ 150 Cr) |
| Offer for Sale | 1,62,65,181 shares of ₹ 2 (agg. up to ₹ 1,607 Cr) |
| Share Holding Pre Issue | 6,16,81,496 shares |
| Share Holding Post Issue | 6,32,02,757 shares |
IPO Important Dates
| IPO Open | Mon, Aug 24, 2026 |
| IPO Close | Thu, Aug 27, 2026 |
| Allotment | Fri, Aug 28, 2026 |
| Refund | Mon, Aug 31, 2026 |
| Credit of Shares | Mon, Aug 31, 2026 |
| Listing | Tue, Sep 1, 2026 |
IPO Lot Size
| Retail (Min) | 1 | 15 | ₹14,820 |
| Retail (Max) | 13 | 195 | ₹1,92,660 |
| S-HNI (Min) | 14 | 210 | ₹2,07,480 |
| S-HNI (Max) | 67 | 1,005 | ₹9,92,940 |
| B-HNI (Min) | 68 | 1,020 | ₹10,07,760 |
Financial Information
| Assets | 1,780.79 | 1,579.65 | 1,294.79 |
| Total Income | 872.26 | 755.98 | 723.33 |
| Profit After Tax | 109.90 | 96.79 | 100.06 |
| EBITDA | 231.97 | 206.11 | 177.04 |
| NET Worth | 1,158.64 | 821.15 | 720.68 |
| Reserves and Surplus | 1,145.95 | 810.03 | 709.54 |
| Total Borrowing | 387.91 | 540.92 | 247.21 |
Key Performance Indicator
| ROE | 11.19% |
| ROCE | 11.56% |
| RoNW | 9.48% |
| PAT Margin | 12.60% |
| EBITDA Margin | 26.59% |
| NAV | 184.69 |
| Price to Book Value | 5.35 |
Information about company
Incorporated in 2002, Symbiotec Pharmalab Ltd. is a pharmaceutical and biotechnology company engaged in the development and manufacturing of active pharmaceutical ingredients (APIs), nutritional ingredients, and specialty products. The company serves domestic and international markets across regulated and emerging regions.
With over 30 years of industry experience, Symbiotec Pharmalab has evolved from a lab-scale steroidal hormone API manufacturer in 1995 into an industrial-scale, backward-integrated manufacturing platform. The company has approvals from the United States Food and Drug Administration (US FDA), European Union Good Manufacturing Practices (EU-GMP), Ministry of Food and Drug Safety, Korea, and other global regulatory organisations.
As of June 30, 2025, the company operated two industrial-scale API manufacturing facilities with a maximum chemical synthesis capacity of 584.67 metric tonnes (MT) and fermentation capacity of 300 kilolitres.
Symbiotec Pharmalab focuses on research-driven manufacturing, quality compliance, and sustainable production processes. It supports the pharmaceutical, nutraceutical, and wellness industries by providing high-quality ingredients aligned with global standards.
Competitive Strengths:
Objectives of IPO
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
#: Issue Objects
1: Prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by the Company
2: General corporate purposes
Disclaimer
All matter published here is purely for educational and information purposes only and under no circumstances should be used for making investment decisions.
We are not a SEBI Registered analyst. Readers must consult a qualified financial advisor prior to making any actual investment decisions, based on Information published on this application.
No financial information whatsoever published anywhere, within this application, should be considered as advice to buy or sell securities or invest in IPOs, or as a guide to doing so in any way whatsoever
Please read all Tearms and conditions , and agree to use the App
Day Wise GMP
| 19-08-2026 | 988 | 150 (15.18%) | 1138 |
IPO Reservation
| QIB | Not more than 50% of the Net Offer |
| Retail | Not less than 35.00% of the Net Offer |
| NII | Not less than 15% of the Net Offer |
